European Pharmaceutical Review
MAY 31, 2023
The inventory position of 28 major pharmaceutical manufacturers in 2022 has been revealed in an annual report. Analysis explored the impact of macro-trends on inventory management from corporate reports of Big Pharma companies including Merck, AstraZeneca and Pfizer. It investigated how excessive inventories are affecting the industry and what factors could influence inventory growth in 2023.
STAT
JUNE 1, 2023
In a bold move, Coherus BioSciences plans to sell a biosimilar version of Humira — one of the world’s best-selling medicines — at a steep discount, and will work with Mark Cuban’s generic drug company to make the medicine available directly to consumers for even less. Specifically, the Coherus medicine will carry a $995 list price for a carton of two autoinjectors, an 85% discount from the $6,922 that AbbVie charges for Humira, which is used to treat rheumatoid arthri
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
ALiEM - Pharm Pearls
JUNE 1, 2023
Are you using phenobarbital instead of benzodiazepines as the first-line monotherapy for patients in alcohol withdrawal in the Emergency Department (ED)? If not, you probably should be. Another old drug for a new indication, right? Well not exactly. Phenobarbital is indeed an older and relatively cheap drug (less than $20 per loading dose) that has gained some press recently for the treatment of acute alcohol withdrawal [1-3].
PharmaVoice
MAY 31, 2023
With the recent approval of Krazati, the biotech veteran is guiding Mirati into its next phase as a commercial-based organization.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
PhRMA
JUNE 2, 2023
With Congress discussing policy changes that would lower drug costs for patients and rein in powerful middlemen, insurers and their PBMs are dusting off their old playbook and once again threatening to increase costs for employers if required to do their job and actually provide meaningful coverage to patients. But recent remarks by one executive make clear that the PBM industry has a choice: protect its profits or lower costs for patients.
STAT
JUNE 2, 2023
Vince Wescott was ready for top surgery. He had the cash saved up, he’d gotten a letter from his therapist, and he’d sent in the required photos of his chest and torso in preparation for a consultation. When his surgeon’s office called unexpectedly, he picked up, assuming that they were missing paperwork or needed to reschedule.
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
PharmaVoice
JUNE 2, 2023
Healthcare pros share the market drivers they believe are having the biggest impact on the industry.
BioPharma Dive
MAY 31, 2023
The biotech, best known for its success developing migraine medicines, will seek approval of a treatment that failed a Phase 3 trial but showed signs of a positive effect.
STAT
JUNE 1, 2023
Tempus, a company that combines DNA sequencing for cancer with artificial intelligence, said Thursday that it is launching a voice-and-text assistant called Tempus One that will give physicians much easier access to patient data. The AI assistant is being launched ahead of the annual meeting of the American Society of Clinical Oncology in Chicago. Eric Lefkofsky, Tempus’ founder and CEO, told STAT Tempus will be rolling the product, called Tempus One, out to the 6,000 doctors that prescri
Pharmaceutical Technology
MAY 30, 2023
SK Bioscience has received marketing authorisation from the UK’s medicines and healthcare products regulatory agency (MHRA) for its Covid-19 vaccine, SKYCovion. SKYCovion is intended for the prevention of Covid-19 resulting from SARS-CoV-2 infection in individuals aged 18 years and above. The authorisation allows the distribution of the vaccine in Scotland, Wales and England.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
PharmaVoice
MAY 30, 2023
Walgreens leaders are not deterred and hope to fill the holes left behind by the pharmacy giant.
BioPharma Dive
JUNE 1, 2023
The biotech will price its biosimilar Yusimry at 85% below Humira’s list price when it launches next month, and charge even less if bought through Mark Cuban’s pharmacy.
STAT
JUNE 1, 2023
Last Thursday, after 15 hours of deliberation, the Indiana State Licensing board ruled that our friend and colleague Caitlin Bernard, an OB-GYN, violated patient privacy laws in discussing the case of a 10-year-old girl who traveled from Ohio for an abortion. She was given a letter of reprimand and a $3,000 fine. While a relatively minor punishment, this finding should send a chill through the medical community and beyond.
Pharmaceutical Technology
MAY 31, 2023
XtalPi has made a partnership deal with US-based Eli Lilly to leverage artificial intelligence (AI) for drug discovery. XtalPi will receive $250m in upfront and milestone payments. The two companies will use XtalPi’s integrated AI capabilities and robotics platform for the de novo [without consideration of previous instances] design and delivery of drug candidates for an undisclosed target.
Pharma Times
JUNE 1, 2023
Nitisinone capsules are indicated for patients with hereditary tyrosinemia type 1 in combination with dietary restriction of tyrosine and phenylalanine
BioPharma Dive
MAY 30, 2023
The biotech said a committee advising the European Medicines Agency is “trending” toward issuing a negative opinion of its drug Relyvrio, which was approved in the U.S. last year.
STAT
JUNE 2, 2023
I’m standing over an operating table, excising a skin cancer from the forehead of an elderly gentleman while soft piano music echoes off the floor tiles. I’ve performed this procedure thousands of times, and I always enjoy the placid focus and deep satisfaction performing cutaneous surgery brings me. All I’ve done in adulthood has brought me here: cadaver prosections in anatomy labs, mentorship from dermatologic surgeons , and mastering various knot-tying techniq
Pharmaceutical Technology
MAY 30, 2023
According to GlobalData’s Looking Ahead to 2023 – the Future of Pharma report, five drugs set for approval in 2023 are projected to attain blockbuster status or near-blockbuster status by 2028 with US company dominance. Lecanemab by Eisai Co Ltd, a monoclonal antibody therapy marketed for Alzheimer’s disease, is predicted to achieve the most significant commercial debut.
Pharma Times
JUNE 2, 2023
The final draft guidance recommends rimegepant for adults who have at least four migraine attacks per month, but less than 15 - News - PharmaTimes
BioPharma Dive
JUNE 2, 2023
Treatment with Kisqali reduced the risk of disease recurrence when used after surgery, potentially positioning Novartis to win a similar adjuvant approval as Lilly’s rival therapy Verzenio.
STAT
JUNE 1, 2023
The statistics are dismal, though they bear repeating: 81% of overdose deaths in the U.S. in 2021 involved an opioid. But as an addiction medicine specialist, there are figures that give me hope: one seminal study showed that 75% of patients who were given the FDA-approved medication buprenorphine to treat opioid use disorder daily for 12 months remained in recovery — compared with 0% who did not receive buprenorphine treatment for the entire 12 months.
PhRMA
MAY 30, 2023
As we recognize Mental Health Awareness Month, I had the opportunity to connect with PhRMA board member Barry Greene, CEO of Sage Therapeutics, about the company’s efforts to address mental health.
Pharma Times
JUNE 1, 2023
Synaffix’s technology platform is intended to enhance and extend Lonza’s integrated ADC services - News - PharmaTimes
BioPharma Dive
MAY 30, 2023
The drug, called marstacimab, outperformed factor treatment in the study, and wasn’t associated with the kind of safety signals that have dogged other medicines in its class.
STAT
MAY 29, 2023
For busy primary care physicians like me, an annual physical with a 27-year-old male is a blessing. Since we’re always running late, a quick visit with a young healthy adult offers the rare chance to get back on schedule. But I didn’t give my own doctor that chance to get back on schedule when I went to see him for my physical a few months ago.
The Honest Apothecary
MAY 27, 2023
As a pharmacist in a management and leadership role, I’m always looking for books with ideas about how to lead better. l love books about creating a better working environment, and anything that may uncover some blindspots I may have about my own organization. When I stumbled across the book Fish! in a thrift store for a mere $2.00 it caught my eye.
Pharma Times
JUNE 2, 2023
BI-1910 is now the second of the company's anti-tumour necrosis factor receptor 2 programmes to enter clinical development - News - PharmaTimes
BioPharma Dive
MAY 31, 2023
The company’s experimental treatment for myotonic dystrophy became the latest neuromuscular disease therapy to face a regulatory roadblock before the start of human testing.
STAT
JUNE 1, 2023
Microsoft-owned Nuance Communications sells its AI medical scribe platform to health care providers on a simple promise: If they shell out big bucks for the high-tech product, they can decrease doctor burnout and ultimately make more money by enabling doctors to see more patients. But executives at four health systems using the software, called DAX, told STAT that while the software might make it possible to see more patients, or justify higher charges to insurers for visits, the high price tag
Pharmaceutical Technology
JUNE 2, 2023
The European Commission (EC) has approved TG Therapeutics’ Briumvi (ublituximab-xiiy) to treat relapsing forms of multiple sclerosis (RMS) in adult patients. Briumvi is an anti-CD20 monoclonal antibody indicated for RMS adult patients with active disease which is defined by clinical or imaging features. It has been engineered to remove certain sugar molecules generally expressed on the antibody.
Commonwealth Pharmacists Association
JUNE 1, 2023
The CPA signs Pioneering Memorandum of Understanding with MOIC Press Release The Commonwealth Pharmacists Association (CPA) is delighted to announce a transformative partnership with the Medicines Optimisation Innovation Centre (MOIC). Formalized through a Memorandum of Understanding (MoU), the partnership aligns with both the CPA and MOIC‘s strategic objectives.
BioPharma Dive
MAY 31, 2023
The shot’s clearance comes several weeks after the regulator made GSK’s Arexvy the first vaccine for RSV in the U.S.
STAT
JUNE 2, 2023
Several years ago, a local artist asked if she could paint my younger daughter, then a tween, as part of a series of life-size portraits of people she knew. Monica Aissa Martinez really gets under her subjects’ skin — the final product is more medical map than pretty picture, documenting the elements (both scientific and ephemeral) that make a person unique.
Pharmaceutical Business Review
MAY 31, 2023
The fundraise saw the participation of new and existing investors Kineticos Ventures and MVM Partners , respectively. Kineticos Ventures president and CEO Frank Lis is joining eXmoor board as a result of the financing. The investment will allow eXmoor to launch its Cell and Gene Therapy Centre, a 65,000ft 2 good manufacturing practice (GMP) facility.
Pharmaceutical Technology
JUNE 1, 2023
The UK’s National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending the use of Pfizer ’s rimegepant (Vydura) to prevent migraine attacks. The therapy has been recommended as an option to prevent episodic migraines in adult patients, who have between four and 15 migraine attacks per month, and where a minimum of three preventive treatments have previously failed.
Expert insights. Personalized for you.
98 
Let's personalize your content